Research
Neural
Tirzepatide is associated with a lower risk of dementia versus semaglutide (HR 0.69, 95% CI 0.48-0.99, p = 0.04).
Practitioners may consider tirzepatide as a potentially safer option for reducing dementia risk in patients with type 2 diabetes.
StrongSupportsmedium confidence
Tirzepatide was associated with a lower risk of dementia versus semaglutide (HR 0.69, 95% CI 0.48-0.99, p = 0.04).
Why this rating
Based on the large cohort study design.
Source
Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study
Alhena Younis et al. · Diabetes Research and Clinical Practice · 2026
DOI 10.1016/j.diabres.2026.113083
cohort · n=14462
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Neural
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →